Dianthus Therapeutics

Dianthus Therapeutics is leading the next generation of complement antibody therapeutics with best-in-class potential to address high unmet medical needs. As a clinical-stage biotechnology company, our mission is focused on designing and delivering novel, best-in-class monoclonal antibodies that utilize the power of selectivity in complement therapeutics. We envision the full potential of complement therapeutics lies within the power of selectivity, specifically through our lead antibody, DNTH103. DNTH103 is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology. This design enables a treatment option that offers less frequent and more convenient self-administered subcutaneous injections, which significantly improves the lives of patients suffering from autoimmune and inflammatory diseases. Dianthus Therapeutics is not just about innovation; it’s the combined effort of a dedicated multidisciplinary team of biotech entrepreneurs and scientists. Together, we are committed to targeting validated and emerging complement targets with improved selectivity and potency over existing therapies. With our headquarters located in New York City and another office in Waltham, MA, we promote a hybrid work environment, fostering creativity and collaboration.